Mambisa, a vaccine candidate developed by the Cuban Center for Genetic Engineering and Biotechnology (CIGB), is one of the five nasal vaccines in the world now in the stage of clinical trial, CIGB director Marta Ayala Avila told the daily Granma.

The five Cuban COVID-19 candidate vaccines have proven to be safe from the scientific, methodological and ethical perpectives, while an ethic committee endorses the quality of research and guarantees the protection of the rights and wellbeing of the volunteers involved in current vaccination trials.

For the world, including Cuba, COVID-19 continues being a major health problem that has not been controlled, considering the number of contagions and deaths that this pandemic has caused for more than a year.

Cuban health minister, Jose Angel Portal Miranda, recognized today the country's psychology professionals, on the occasion of the National Day of this specialty.

Cuba studied 21,399 samples for COVID 19, resulting in 1,060 positive ones. The country accumulates 3, 256,543 samples taken and 88,445 positive.

Cuban Foreign Minister Bruno Rodriguez stressed the assistance of all physically challenged persons on the island, while in today’s world those citizens face lots of difficulties.

The Phase II clinical trials of Soberana Plus in convalescents of COVID 19 will include 450 people and will broaden the inclusion criteria compared to Phase I, informed today an expert from the Finlay Vaccine Institute (IFV), the entity that developed this vaccine candidate against COVID-19.

Experts with the BioCubaFarma Biotech conglomerate said on Monday that the second dose of the locally developed COVID-19 vaccines Soberana 02 and Abdala keep advancing as scheduled.

Cuba studied 21,799 samples for COVID 19, resulting in 854 positive ones. The country accumulates 3,235,144 samples taken and 87,385 positive.

Thanks to the opportune assistance of patients and the active work of specialized medical personnel, premature mortality due to breast cancer has been reduced in Santiago de Cuba.

The country accumulates 10,766 cases of people diagnosed with Covid-19 in pediatric ages, an extremely high figure, according to Cuban experts, which is why they are calling attention to this phenomenon.

Health personnel from Havana and Biocubafarma, participating in the intervention study of Soberana 02 and Abdala, two of Cuba's anti-COVID-19 candidates, are currently vaccinated with the first dose.

With the inauguration this Saturday of the Laboratory of Molecular and Cellular Biology in Las Tunas, almost all Cuban provinces now have facilities of this type for the processing of samples for the detection of COVID-19 and the study of other specialties such as Oncology and Genetics.

Cuba's Center for State Control of Medicines, Equipment and Medical Devices (CECMED) approved the Phase II clinical trial of the Cuban anti-COVID-19 vaccine candidate Soberana Plus.